<DOC>
	<DOCNO>NCT00320073</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , vinflunine , work different way stop growth tumor cell , either kill cell stop dividing . Erlotinib pemetrexed may stop growth tumor cell block enzymes need cell growth . Giving vinflunine together erlotinib pemetrexed may kill tumor cell . PURPOSE : This phase I trial study side effect best dose vinflunine give together erlotinib pemetrexed treat patient unresectable metastatic solid tumor .</brief_summary>
	<brief_title>Vinflunine Erlotinib Pemetrexed Treating Patients With Unresectable Metastatic Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Define maximum tolerate dose ( MTD ) vinflunine pemetrexed disodium patient unresectable metastatic solid tumor . - Define MTD vinflunine erlotinib hydrochloride patient . Secondary - Determine preliminary safety efficacy ( report descriptively per patient response ; tumor specific response rate report applicable ) regimens . - Correlate CYP3A4 activity , measure midazolam clearance , vinflunine plasma clearance . OUTLINE : This nonrandomized , open-label , dose-escalation study . Patients assign 1 2 treatment group . - Group 1 : Patients receive pemetrexed disodium IV 10 minute vinflunine IV 20 minute day 1 . Cohorts 3-6 patient receive escalate dos pemetrexed disodium vinflunine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Additional patient may treat MTD . - Group 2 : Patients receive vinflunine IV 20 minute day 1 oral erlotinib hydrochloride daily day 2-21 course 1 day 1-21 subsequent course . Cohorts 3-6 patient receive escalate dos erlotinib hydrochloride vinflunine MTD determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Additional patient may treat MTD . In group , course repeat every 21 day absence unacceptable toxicity . Blood sample collect day 1 course 1 pharmacodynamic study . After completion study treatment , patient follow 30-40 day .</detailed_description>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm solid tumor Advanced/unresectable metastatic disease Refractory standard therapy OR standard therapy exist No lymphoma Measurable evaluable disease Measurable disease define least one target lesion measure ≥ 20 mm conventional technique ≥ 10 mm spiral CT scan Evaluable disease include ascites , pleural effusion , bone metastasis , pulmonary lymphangitic spread , lesion meet criterion measurable Patients clinically significant ascites pleural effusion control drainage eligible Brain metastasis allow CNSdirected treatment give , patient CNSdirected therapy &gt; 3 month , CNS disease clinically radiographically stable least 8 week PATIENT CHARACTERISTICS : Life expectancy &gt; 3 month ECOG performance status 02 Absolute neutrophil count ≥ 1,500/μL Platelet count ≥ 100,000/μL Creatinine clearance ≥ 60 mL/min Patients assign group 1 creatinine clearance 4580 mL/min must able withhold NSAIDS pemetrexed disodium administration Total bilirubin ≤ 1.5 mg/dL AST ALT ≤ 3 time upper limit normal ( ULN ) OR ≤ 5 time ULN due know liver metastases No New York Heart Association class III IV heart failure No unstable angina No myocardial infarction within past 6 month No poorly control hypertension No prior allergic reaction vinca alkaloid No uncontrolled active infection severe illness Able receive vitamin B12 folate supplementation dexamethasone chemotherapy Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month last dose chemotherapy PRIOR CONCURRENT THERAPY : At least 4 week since prior chemotherapy , investigational agent , surgery Concurrent cytochrome P450/CYP3A4 inducer inhibitor allow provided patient stable dose ≥ 2 week prior study entry No concurrent ketoconazole , itraconazole , ritonavir , amprenavir , indinavir No concurrent enzymeinducing antiepileptic drug ( EIAEDs ) ( e.g. , phenytoin , carbamazepine , phenobarbital , primidone , oxcarbazepine ) patient assign group 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>